發送短信 : A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost

 _____     _    _     ______     ___    __    __  
|  __ \\  | || | ||  /_____//   / _ \\  \ \\ / // 
| |  \ || | || | ||  `____ `   | / \ ||  \ \/ //  
| |__/ || | \\_/ ||  /___//    | \_/ ||   \  //   
|_____//   \____//   `__ `      \___//     \//    
 -----`     `---`    /_//       `---`       `     
                     `-`